

Can Vaccines Protect Your Brain? What the Latest Research Shows

It's one of the more surprising threads in recent dementia prevention research: several common adult vaccines — ones many people already get for entirely different reasons — appear to be linked to a meaningfully lower risk of dementia. The evidence has been building quickly, and it now spans multiple vaccines, multiple countries, and millions of people.

Shingles Vaccine: The Strongest and Fastest-Growing Evidence

The shingles vaccine currently has the most compelling evidence behind it — and some of the most rigorous study design. At the 2026 American Academy of Neurology annual meeting, Stanford researcher Dr. Pascal Geldsetzer presented findings using a particularly clever approach: rather than simply comparing people who chose to get vaccinated against those who didn't (which can be skewed by all sorts of other health and lifestyle differences), his team compared people who were just above versus just below the age cutoff for Canada's 2016 shingles vaccination program. This kind of "natural experiment" design gets researchers much closer to genuine cause-and-effect. The result: a 20% reduction in new dementia diagnoses over seven years among those who received the vaccine.

A separate, more recent study published in the *Annals of Internal Medicine* in June 2026, using Medicare data, found a 24% lower relative risk of dementia among vaccinated beneficiaries — adding further weight to the pattern.

Perhaps most exciting: Geldsetzer's team has also found evidence that the vaccine's benefit may not stop at prevention. New findings suggest it may have therapeutic potential too, with large reductions observed in the risk of dying from dementia among people already diagnosed. Separately, a January 2026 study found the shingles vaccine may even help slow biological aging more broadly.

Flu Vaccine: A Clear Dose-Response Pattern

Flu vaccination has been studied more extensively than any other vaccine in relation to dementia risk. A 2022 study analyzing nearly 2 million people aged 65 and older found that those who received at least one flu vaccine were 40% less likely to develop Alzheimer's over four years — and the more frequently people were vaccinated, the greater the protection appeared to be.

The story continued in April 2026, when the same research team published new findings in *Neurology* showing that the high-dose flu vaccine — which contains four times the antigen of a standard shot, designed to produce a stronger immune response in older adults — was linked to a 55% reduced risk, notably outperforming the standard-dose vaccine.

A Surprising New Lead: RSV Vaccine and a Shared Ingredient

One of the more intriguing recent developments involves the RSV vaccine, Arexvy. Researchers noticed that it showed protective effects similar in magnitude to the shingles vaccine — despite targeting a completely different virus. The common thread: both vaccines contain the same immune-boosting adjuvant, called AS01. This overlap has led researchers to float a compelling hypothesis — that the adjuvant itself, which stimulates a stronger immune response, may be doing meaningful protective work on its own, independent of which specific virus the vaccine is designed to target.

The Pattern Now Spans at Least Eight Vaccines

Beyond shingles, flu, and RSV, researchers have identified similar associations with pneumococcal vaccines and DTP (diphtheria-tetanus-pertussis) vaccines. This is no longer an isolated finding tied to one vaccine — it's a consistent pattern showing up across multiple vaccine types, multiple countries, and millions of people studied.

What Might Explain the Connection

Researchers currently point to two possible explanations, and they aren't mutually exclusive:

Preventing infection-driven brain inflammation. Certain infections are known to trigger inflammation that can damage brain tissue over time. By preventing the infection itself, the vaccine may be preventing this downstream inflammatory damage.

A broader, general immune-system effect. The AS01 adjuvant finding hints at something bigger — that vaccination may trigger beneficial immune system changes that offer some protective effect regardless of the specific pathogen being targeted.

Given how many different types of vaccines show this pattern, many researchers currently suspect some combination of both mechanisms is likely at play.

Why This Matters

With more than 57 million people living with dementia worldwide, and roughly 10 million new cases diagnosed every year, even a modest protective effect from something as accessible, low-risk, and already widely recommended as routine adult vaccination represents a genuinely significant public health opportunity — one that requires no new behavior change, medication, or lifestyle shift beyond staying current on vaccines already recommended for other health reasons.

The Takeaway

The evidence connecting vaccination to lower dementia risk has moved quickly from an interesting observation to a well-replicated pattern backed by increasingly rigorous study designs. While researchers continue to refine exactly how and why this protection occurs, staying current on recommended vaccines — shingles, flu, RSV, and others — may be doing more for your long-term brain health than most people realize.

It's never too late to protect your brain, one shot at a time.

References

1. Eight Vaccines Linked to a Lower Risk of Dementia. Gavi, the Vaccine Alliance. 2026.
 2. AAN 2026: Shingles Vaccine May Protect Against Dementia. Doximity Op-Med. 2026.
 3. More Evidence Ties Shingles Vax to Lower Dementia Risk. Medscape. 2026.
 4. Vaccination Linked to Changes in Dementia Risk in New Study. HelpDementia.com. 2026.
 5. Shingles Vaccination Linked to Lower Dementia Risk, More Evidence Suggests. Medical News Today. 2026.
-

Brain Health for Life™ | Brain Health Forum